524 related articles for article (PubMed ID: 25592291)
21. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
22. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
[TBL] [Abstract][Full Text] [Related]
23. P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis.
McHenry PR; Sears JC; Herrick MP; Chang P; Heckman-Stoddard BM; Rybarczyk M; Chodosh LA; Gunther EJ; Hilsenbeck SG; Rosen JM; Vargo-Gogola T
Breast Cancer Res; 2010; 12(5):R73. PubMed ID: 20860838
[TBL] [Abstract][Full Text] [Related]
24. Periostin contributes to the acquisition of multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells.
Wang X; Liu J; Wang Z; Huang Y; Liu W; Zhu X; Cai Y; Fang X; Lin S; Yuan L; Ouyang G
PLoS One; 2013; 8(8):e72962. PubMed ID: 24009721
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
Croci S; Nanni P; Palladini A; Nicoletti G; Grosso V; Benegiamo G; Landuzzi L; Lamolinara A; Ianzano ML; Ranieri D; Dall'Ora M; Iezzi M; De Giovanni C; Lollini PL
Breast Cancer Res; 2015 May; 17(1):70. PubMed ID: 25997501
[TBL] [Abstract][Full Text] [Related]
26. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
27. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
Shim HS; Jung WH; Kim H; Park K; Cho NH
APMIS; 2006 May; 114(5):352-8. PubMed ID: 16725011
[TBL] [Abstract][Full Text] [Related]
28. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
Turpin J; Ling C; Crosby EJ; Hartman ZC; Simond AM; Chodosh LA; Rennhack JP; Andrechek ER; Ozcelik J; Hallett M; Mills GB; Cardiff RD; Gray JW; Griffith OL; Muller WJ
Oncogene; 2016 Nov; 35(47):6053-6064. PubMed ID: 27157621
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
30. Involvement of Notch1 in the development of mouse mammary tumors.
Diévart A; Beaulieu N; Jolicoeur P
Oncogene; 1999 Oct; 18(44):5973-81. PubMed ID: 10557086
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors.
Hu C; Diévart A; Lupien M; Calvo E; Tremblay G; Jolicoeur P
Am J Pathol; 2006 Mar; 168(3):973-90. PubMed ID: 16507912
[TBL] [Abstract][Full Text] [Related]
32. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.
Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV
BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536
[TBL] [Abstract][Full Text] [Related]
33. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours.
Schmitt FC; Soares R; Seruca R
Virchows Arch; 1998 Dec; 433(6):505-9. PubMed ID: 9870682
[TBL] [Abstract][Full Text] [Related]
34. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
Wang QF; Ding H; Liu BR; Zhang K
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
[TBL] [Abstract][Full Text] [Related]
35. HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis.
Tekmal RR; Nair HB; Perla RP; Kirma N
J Steroid Biochem Mol Biol; 2007; 106(1-5):111-8. PubMed ID: 17604617
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
37. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
38. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract][Full Text] [Related]
39. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.
Maroulakou IG; Oemler W; Naber SP; Tsichlis PN
Cancer Res; 2007 Jan; 67(1):167-77. PubMed ID: 17210696
[TBL] [Abstract][Full Text] [Related]
40. Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer.
Grosset AA; Poirier F; Gaboury L; St-Pierre Y
PLoS One; 2016; 11(11):e0166731. PubMed ID: 27902734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]